The Integration of PD1 blockade with epigenetic therapy is highly active and safe in heavily treated patients with T-cell lymphoma (PTCL) and cutaneous T-cell lymphoma (CTCL).

Enrica Marchi,Helen Ma,Francesca Montanari,Ahmed Sawas,Jennifer Kimberly Lue,Changchun Deng,Kareema T Whitfield,Sandra Klein,Luigi Scotto,Salvia Jain,John Lister,Nora N Benanni,Mark A. Francescone,Won-Seog Kim,Pier Luigi Zinzani,Owen A. OConnor

The Integration of PD1 blockade with epigenetic therapy is highly active and safe in heavily treated patients with T-cell lymphoma (PTCL) and cutaneous T-cell lymphoma (CTCL).

2020

Enrica Marchi
Helen Ma
Francesca Montanari
Ahmed Sawas
Jennifer Kimberly Lue
Changchun Deng
Kareema T Whitfield
Sandra Klein
Luigi Scotto
Salvia Jain
John Lister
Nora N Benanni
Mark A. Francescone
Won-Seog Kim
Pier Luigi Zinzani
Owen A. OConnor

8049Background: Our group has demonstrated that combinations of epigenetic modifiers produce potent synergy in pre-clinical models of PTCL and induce the expression of cancer testis antigen, sugges...

Keywords:

Epigenetic therapy
T-cell lymphoma
Cancer research
Medicine
Blockade
Cutaneous T-cell lymphoma
Pathology

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations